Geron Posts $1.4 Million Quarterly Profit As Rytelo Sales Reach $60.1 Million
The blood-cancer drugmaker swung from an $18.4 million loss a year earlier and lowered its 2026 operating expense range to $220 million to $230 million.
Geron, which sells the blood-cancer drug Rytelo, reported net income of $1.4 million for the third quarter, against an $18.4 million loss a year earlier, according to an 8-K it filed Wednesday. The company also lowered its 2026 operating expense forecast.
Sales up, costs down
Rytelo net product revenue was $60.1 million, up 5% from the second quarter and compared with $47.2 million in the third quarter of 2025. Total costs and operating expenses fell to $54.4 million from $61.1 million, on lower personnel and clinical development spending, partly offset by non-cash inventory-related expenses.
Research and development spending dropped to $12.7 million from $21.1 million. Selling, general and administrative costs fell to $35.7 million from $39.0 million. Cost of goods sold rose to about $6.1 million from $1.0 million, which the company attributed mainly to the non-cash inventory charges.
For the first nine months, Geron still posted a net loss of $19.0 million, compared with $54.6 million a year earlier.
Demand and the guidance change
Rytelo demand grew 10% from the second quarter, and ordering accounts rose roughly 8% to approximately 1,700. CEO Harout Semerjian said the growth is coming from community practices, which "indicates the potential for RYTELO to have a long growth runway in the U.S."
Geron reiterated that 2026 Rytelo net product revenue should land at the mid-to-high end of $220 million to $240 million. It now expects total operating expenses of $220 million to $230 million, down from $230 million to $240 million. Cash and marketable securities stood at $339.4 million on September 30, up from $326.9 million on June 30.
A myelofibrosis setback, a European launch
Geron is a hematology-focused company whose Rytelo is approved in the US for adults with lower-risk myelodysplastic syndromes, a group of blood cancers, who have transfusion-dependent anemia. During the quarter it discontinued the late-stage IMpactMF trial in relapsed or refractory myelofibrosis, after an independent monitoring committee said the trial was unlikely to meet its main goal of overall survival. The company said no new safety signals emerged, does not expect to pursue an approval pathway in that disease, and is increasingly dependent on Rytelo in lower-risk MDS.
Geron has also started a gated commercial launch in targeted European markets. Rytelo is expected to be available in Germany by the end of the year and in France in 2027.
Geron said it will fund operations for the foreseeable future from its cash and anticipated US Rytelo revenue.
Sources
- 8-K Filing — GERON CORP (GERN) — SEC EDGAR
- Exhibit d188608dex991.htm — GERON CORP 8-K exhibit — SEC EDGAR